Zevra Therapeutics (ZVRA) Retained Earnings (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Retained Earnings of -$384.2 million for Q1 2026, up 8.98% on a QoQ basis from -$422.1 million in Q4 2025, and down 468400.0% year-over-year from N/an in Q1 2025.
Zevra Therapeutics (ZVRA) Retained Earnings (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Retained Earnings history runs 13 years deep, the most recent figure standing at -$384.2 million for Q1 2026.
- Quarterly Retained Earnings fell 468400.0% year-over-year to -$384.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$384.2 million (down 468400.0% YoY) and the FY2025 annual result came in at -$422.1 million, down 66987.48% from the prior year.
- Retained Earnings was -$384.2 million for Q1 2026 at Zevra Therapeutics, up from -$422.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $631000.0 in Q4 2024 and bottomed at -$469.6 million in Q3 2024.
- A 5-year average of -$268.2 million and a median of -$346.1 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings jumped 100.16% — and 2026, when it tumbled 468400.0%.
- Zevra Therapeutics' Retained Earnings stood at -$353.7 million in 2022, then declined by 13.02% to -$399.8 million in 2023, then soared by 100.16% to $631000.0 in 2024, then tumbled by 66987.48% to -$422.1 million in 2025, then rose by 8.98% to -$384.2 million in 2026.
- Business Quant data shows ZVRA's Retained Earnings at -$384.2 million in Q1 2026, -$422.1 million in Q4 2025, and -$434.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | -384.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -384.17 Mn |
| Dec 31, 2025 | -422.06 Mn |
| Sep 30, 2025 | -434.23 Mn |
| Jun 30, 2025 | -433.68 Mn |
| Mar 31, 2025 | -82,000.00 |
| Dec 31, 2024 | 631,000.00 |
| Sep 30, 2024 | -469.60 Mn |
| Jun 30, 2024 | -436.33 Mn |
| Mar 31, 2024 | 141,000.00 |
| Dec 31, 2023 | -399.78 Mn |
| Sep 30, 2023 | -220,000.00 |
| Jun 30, 2023 | -225,000.00 |
| Mar 31, 2023 | -320.34 Mn |
| Dec 31, 2022 | -353.73 Mn |
| Sep 30, 2022 | -299.55 Mn |
| Jun 30, 2022 | -338.44 Mn |
| Sep 30, 2021 | -264.33 Mn |
| Jun 30, 2021 | -262.57 Mn |
| Mar 31, 2021 | -268.77 Mn |
| Dec 31, 2020 | -258.47 Mn |